The Catecholamine Working Group recommends the implementation of spot urine as standard of care. ConclusionĬatecholamine metabolites in spot urine and 24-hour urine resulted in similar diagnostic sensitivities. No differences were observed in metabolite levels between the two analysis methods. The area under the receiver-operating-characteristic curve (AUC) of the panel containing all eight catecholamine metabolites was significantly higher compared to that of only HVA and VMA (AUC = 0.952 vs. Excretion levels of catecholamine metabolites and the diagnostic sensitivity for each metabolite were similar in 24-hour urine and spot urine samples ( p >. ResultsĬatecholamine metabolite levels were measured in urine samples of 400 neuroblastoma patients (24-hour urine, n = 234 spot urine, n = 166) and 571 controls (all spot urine). Homovanillic acid (HVA), vanillylmandelic acid (VMA), dopamine, 3-methoxytyramine, norepinephrine, normetanephrine, epinephrine and metanephrine were measured by high-performance liquid chromatography coupled with fluorescence detection (HPLC-FD) and/or ultra-performance liquid chromatography coupled with electrospray tandem mass spectrometry (UPLC-MS/MS). Twenty-four-hour urine or spot urine samples were collected from patients with and without neuroblastoma at diagnosis. We investigated if spot urine samples can be reliably used for analysis of a panel of catecholamine metabolites for the diagnosis of neuroblastoma. Currently, there is no consensus regarding the sampling method, and variable combinations of catecholamine metabolites are being used. The analysis of urinary catecholamine metabolites is a cornerstone of neuroblastoma diagnostics.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |